Literature DB >> 18194834

A mechanism for the anti-fibrogenic effects of the pregnane X receptor (PXR) in the liver: inhibition of NF-kappaB?

A Axon1, D E Cowie, D A Mann, M C Wright.   

Abstract

The liver is susceptible to chronic damage through exposure to a variety of toxins (e.g. alcohol) and viruses (e.g. hepatitis C). Obesity, autoimmune diseases (e.g. autoimmune hepatitis) and a variety of genetic diseases (e.g. Wilson's disease) also lead to chronic liver damage. This damage results in scarring fibrogenesis, structural disruption and functional impairment of the organ. Recent work suggests that there is cross-talk between the PXR and NF-kappaB pathways. This cross-talk may explain the observation that PXR activators inhibit liver fibrosis in in vitro and in vivo animal models of the disease. This reveiw will focus on the two transcription factors and their potential interaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18194834     DOI: 10.1016/j.tox.2007.12.008

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  6 in total

1.  SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts.

Authors:  Barbara Renga; Andrea Mencarelli; Marco Migliorati; Sabrina Cipriani; Claudio D'Amore; Eleonora Distrutti; Stefano Fiorucci
Journal:  Inflamm Res       Date:  2011-01-29       Impact factor: 4.575

Review 2.  Pregnane X receptor as a target for treatment of inflammatory bowel disorders.

Authors:  Jie Cheng; Yatrik M Shah; Frank J Gonzalez
Journal:  Trends Pharmacol Sci       Date:  2012-05-18       Impact factor: 14.819

3.  Pregnane X receptor is SUMOylated to repress the inflammatory response.

Authors:  Gang Hu; Chenshu Xu; Jeff L Staudinger
Journal:  J Pharmacol Exp Ther       Date:  2010-08-18       Impact factor: 4.030

Review 4.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 5.  Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.

Authors:  Arunima Biswas; Sridhar Mani; Matthew R Redinbo; Matthew D Krasowski; Hao Li; Sean Ekins
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

6.  Sustained Isoprostane E2 Elevation, Inflammation and Fibrosis after Acute Ischaemia-Reperfusion Injury Are Reduced by Pregnane X Receptor Activation.

Authors:  Aimen O Amer; Philip M Probert; Michael Dunn; Margaret Knight; Abigail E Vallance; Paul A Flecknell; Fiona Oakley; Iain Cameron; Steven A White; Peter G Blain; Matthew C Wright
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.